Table 3 Protocol for MGIT-DST of MDR-Mtb with DFO-B alone and in combination with INH and RIF
No | Drug | Initial Concentration of the drug preparation | Volume added to MGIT for Test | Final Concentration in MGIT tube except GC | No. of Middle Brook tubes | |
|---|---|---|---|---|---|---|
GC | MDR | |||||
1 | INH | 8.3 μg/mL | 100 μL | 0.1 μg/mL | 1 | 1 |
2 | RIF | 83 μg/mL | 100 μL | 1.0 μg/mL |  | 1 |
3 | DFO-B + INH | 160 mg/mL + 8.3 μg/mL | 12.5 μL + 100 μL | 0.25 mg/mL and 0.1 μg/mL |  | 1 |
4 | DFO-B + INH | 160 mg/mL + 8.3 μg/mL | 25 μL and 100 μL | 0.5 mg/mL and 0.1 μg/mL |  | 1 |
5 | DFO-B + INH | 160 mg/mL + 8.3 μg/mL | 50 μL and 100 μL | 1.0 mg/mL and 0.1 μg/mL | 1 | 1 |
6 | DFO-B + RIF | 160 mg/mL + 83 μg/mL | 12.5 μL + 100 μL | 0.25 mg/mL and 1.0 μg/mL |  | 1 |
7 | DFO-B + RIF | 160 mg/mL + 83 μg/mL | 25 μL + 100 μL | 0.5 mg/mL and 1.0 μg/mL |  | 1 |
8 | DFO-B + RIF | 160 mg/mL + 83 μg/mL | 50 μL + 100 μL | 1.0 mg/mL and 1.0 μg/mL |  | 1 |
9 | DFO-B | 160 mg/mL | 12.5 μL | 0.25 mg/mL | 1 | 1 |
10 | DFO-B | 160 mg/mL | 25 μL | 0.5 mg/mL |  | 1 |
11 | DFO-B | 160 mg/mL | 50 μL | 1.0 mg/mL |  | 1 |
12 | DFO-B + FeCl3 | 160 mg/mL + 80 mg/mL | 50 μL + 50 μL | 1.0 mg/mL and 0.5 mg/mL |  | 1 |